CombiMatrix Announces Partnership With ProPath to Provide Products of Conception Testing
14 Enero 2014 - 5:00AM
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for
developmental disorders and cancer diagnostics, today announced
that it has been selected by ProPath® to provide its chromosomal
microarray analysis (CMA) testing for miscarriage analysis for
ProPath patients. ProPath, based in Dallas, is a wholly
physician-owned provider of pathology services to clinicians,
hospitals, reference laboratories and medical facilities
nationwide.
ProPath Women's Health Director, Kenneth E. Youens, M.D., said
that ProPath is committed to providing comprehensive, high quality
diagnostics services and CMA testing for miscarriage analysis. Also
called Products of Conception (POC) testing, this will be an
important new addition to ProPath's suite of women's health
diagnostics.
"For an important group of patients, CMA testing can play a
significant role in a comprehensive miscarriage analysis," Dr.
Youens said. "At ProPath, we set a very high standard in terms of
offering the most advanced testing and diagnostic services. The
accuracy, clinical utility and quick turnaround times of CMA
testing makes it a superior first tier testing option. We are very
excited to offer CMA testing for miscarriage analysis and to be
working closely with CombiMatrix to provide this important
service."
CombiMatrix President and CEO, Mark McDonough noted that the
partnership with ProPath is yet another validation of the quality
of diagnostic services that CombiMatrix provides and the importance
of CMA testing in the modern healthcare market. "CMA testing for
genetic abnormalities is quickly becoming the standard of care at
leading diagnostic labs throughout the country," McDonough said.
"CMA is especially important in the case of stillbirths or
miscarriages because it can provide parents valuable information
about future pregnancies. We look forward to working closely with
the physicians and clinicians at ProPath."
About ProPath
ProPath is the premier team of pathologists providing outpatient
anatomic and full-service, hospital-based pathology services to
physicians, surgery centers, hospitals and reference laboratories
nationwide. With headquarters in Dallas, Texas, our practice and
internationally recognized Immunohistochemistry laboratory have
some of the most competitive turnaround times for routine
specimens. ProPath is a wholly physician-owned pathology group that
remains devoted to comprehensive, quality diagnostic services for
unsurpassed patient care. We have been providing reliable and
convenient pathology services since 1966. ProPath is accredited by
the College of American Pathologists (CAP), and the Department of
Human Services in Accordance with the Clinical Laboratory
Improvement Amendments of 1988 (CLIA). We follow comprehensive
quality control and quality improvement programs. Our team of
nearly 40 board certified pathologist has subspecialty training and
expertise in Dermatopathology, Renal Pathology, Hematopathology,
Gastrointestinal Pathology, Urologic Pathology,
Immunohistochemistry, Cytopathology, Surgical Pathology, Breast
Pathology and Molecular Diagnostics. For more information about
ProPath, please visit http://www.propath.com.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic
solutions and comprehensive clinical support for the highest
quality of care – specializing in miscarriage analysis, prenatal
and pediatric healthcare. CombiMatrix offers comprehensive testing
services for the detection of genetic abnormalities at the DNA
level, beyond what can be identified through traditional
methodologies. The Company performs genetic testing utilizing
advanced technologies, including microarray, FISH, PCR and G-Band
chromosome analyses. Additional information about CombiMatrix is
available at www.combimatrix.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can often be
identified by words such as "anticipates," "expects," "intends,"
"plans," "goal," "predicts," "believes," "seeks," "estimates,"
"may," "will," "should," "would," "could," "potential," "continue,"
"ongoing," "objective," similar expressions, and variations or
negatives of these words and include, but are not limited to,
statements regarding the access to our services for ProPath
physicians. These forward-looking statements are not guarantees of
future results and are subject to risks, uncertainties and
assumptions that could cause our actual results to differ
materially and adversely from those expressed in any
forward-looking statement. The risks and uncertainties
referred to above include, but are not limited to: use of our
services by ProPath patients; market acceptance of CMA as a
superior method of molecular diagnostic testing; our ability to
successfully expand the base of our customers and strategic
partners, add to the menu of our diagnostic tests in both of our
primary markets, develop and introduce new tests and related
reports, optimize the reimbursements received for our testing
services, and increase operating margins by improving overall
productivity and expanding sales volumes; our ability to
successfully accelerate sales, allow access to samples earlier in
the testing continuum, steadily increase the size of our customer
rosters in both developmental medicine and oncology; our ability to
attract and retain a qualified sales force; rapid technological
change in our markets; changes in demand for our future products;
legislative, regulatory and competitive developments; general
economic conditions; and various other factors. Further
information on potential factors that could affect our financial
results is included in our Annual Report on Form 10-K, Quarterly
Reports of Form 10-Q, and in other filings with the Securities and
Exchange Commission. We undertake no obligation to revise or
update publicly any forward-looking statements for any reason,
except as required by law.
CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624
Investor Contact:
Matt Clawson
Partner
Allen & Caron
Tel (949) 474-4399
Matt@allencaron.com
Media Contact:
Len Hall
VP, Media Relations
Allen & Caron
Tel (949) 474-4300
len@allencaron.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2024 a Jul 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024